Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma
- Author:
Yu WEI-BO
1
;
Rao JIAN-YU
1
Author Information
1. Department of Pathology and Laboratory Medicine,David Geffen School of Medicine University of California at Los Angeles,10833 Le Conte Ave.,Los Angeles,CA 90095,USA
- Publication Type:Journal Article
- Keywords:
Immune checkpoint therapy;
Urothelial carcinoma;
Bladder cancer;
Programmed death-ligand 1;
Programmed death-1
- From:
Chronic Diseases and Translational Medicine
2019;5(3):170-177
- CountryChina
- Language:English
-
Abstract:
After two decades of unchanged paradigms, the treatment strategies for advanced urothelial bladder cancer have been revolu-tionized by emerging programmed death ligand-1 (PD-L1)/programmed death-1 (PD1) inhibition therapy. Increased evidence is demonstrating the efficacy of PD-L1/PD1 inhibition therapy in both second-line and first-line settings. However, the percentage of patients who benefit from anti-PD-L1/anti-PD1 therapy is still low. Many questions have been raised in the development of biomarker-driven approaches for disease classification and patient selection. In this perspective, we discuss PD-L1/PD1 expression in urothelial bladder carcinoma, review approved anti-PD-L1/anti-PD1 agents for bladder cancer treatment and current ongoing studies investi-gating combination treatment strategies, and explore PD-L1 expression status for the evaluation of bladder cancer immunotherapy.
